Ustekinumab biosimilar is under clinical development by STgen Bio and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Pre-Registration drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Ustekinumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ustekinumab biosimilar overview
Ustekinumab biosimilar is under development for the treatment of plaque psoriasis, Crohn's disease, psoriatic arthritis and ulcerative colitis. It is administered through subcutaneous route. The drug candidate acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha.
STgen Bio overview
STgen Bio, formerly DM Bio, is a bio pharmaceutical manufacturing company involved in providing various contract manufacturing services ranging from pre-clinical services to sale of in market bio pharmaceutical products. The company is headquartered in Incheon, Seoul, South Korea.
For a complete picture of Ustekinumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.